Who We Are

About Us

Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. Our therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world, we are developing a series of potentially first-in-class therapeutics.

Management Team

Diverse Expertise, Singular Vision

  Genetics and AMD
GENETICS AND AMD
Target Biology
TARGET BIOLOGY
Technology
TECHNOLOGY
SCIENTIFIC FOUNDERS Johanna M. Seddon, M.D., Sc.M.
Tufts University
Paul Barlow, Ph.D.
The University of Edinburgh

Andrew Herbert, Ph.D.
The University of Edinburgh

SCIENTIFIC ADVISORY BOARD MEMBERS Dean Bok, Ph.D.
UCLA

Bruce Jaffee, Ph.D.


Napoleone Ferrara, M.D.
University of California San Diego

Alan Wright, M.B., Ch.B., Ph.D.
The University of Edinburgh

John Atkinson, M.D.
Washington University in St. Louis

Michael Ehrmann, Ph.D.
University of Essen-Duisberg

Kevin Marchbank, Ph.D.
Newcastle University

Diana Wouters, Ph.D.
Sanquin

Aravind Asokan, Ph.D.
University of North Carolina

Shannon Boye, Ph.D.
University of Florida

Claudio Punzo, Ph.D.
University of Massachusetts Medical School

Chris Mueller, Ph.D., Sc.M.
University of Massachusetts Medical School

SCIENTIFIC FOUNDERS

GENETICS AND AMD
TARGET BIOLOGY

SCIENTIFIC ADVISORY BOARD MEMBERS

GENETICS AND AMD
TARGET BIOLOGY
TECHNOLOGY

Board of Directors

Our Investors

We are proud to be funded by leading life science investors, including:

  • Atlas Venture
  • Lightstone
  • OrbiMed

What Inspires Us?

Adarsha Koirala

Adarsha Koirala
Senior Scientist

“I am inspired by my colleagues who are passionately working towards the common goal of developing therapies for AMD. With our precision approach and modality agnostic strategy, we’re finding new ways to treat this debilitating disease.”

Scott Lauder

Scott Lauder
Senior Vice President

“I really like being part of a company that has been built from the disease perspective rather than around a technology — especially one that can have such a big impact on a large and largely underserved patient population.”

Robyn Biggs

Robyn Biggs
Principal Scientist

“I enjoy the fast-paced, team-oriented culture of Gemini. The biology of our targets is de-risked by human genetics, and we’re all focused on delivering therapeutics against those targets.”

See Yourself Joining the Gemini Team?

We are looking for talented, passionate individuals to help us develop new precision therapeutics for AMD. To learn more, please contact us at: careers@geminitherapeutics.com